Researchers identify early warning sign that triggers rheumatoid arthritis
Scientists have discovered that a specific antibody appears in the blood before rheumatoid arthritis develops, potentially allowing doctors to identify and treat patients years before symptoms begin. The finding could reshape how companies develop RA diagnostics and preventive therapies, opening a new market for early-stage disease intervention.
Originaltitel: The role of IgM anti-acetylated protein antibodies and B cells in the origin of antimodified protein autoimmunity in rheumatoid arthritis
<p>Objective: Rheumatoid arthritis (RA) is characterized by anti-modified protein antibodies (AMPAs), including anti-citrullinated protein antibodies (ACPA), anti-carbamylated protein antibodies (anti-CarP), and anti-acetylated protein antibodies (AAPA). In contrast to other AMPAs, AAPA IgM is found in healthy individuals, raising questions about its role in early immune responses. We investigated whether AAPA IgM serves as a precursor for other AMPAs, marking the initial breach of tolerance in RA.</p><p>Methods: AAPA IgM levels were measured in cord blood and serum of children up to three years old to assess whether it represents a natural (auto)antibody. To evaluate whether AAPA IgM presence precedes other AMPAs, we longitudinally measured AAPA and ACPA IgM in individuals before RA onset. To assess whether AAPA IgM–expressing B cells display a naive phenotype and carry germline-encoded B cell receptors (BCRs), single cells were sorted and sequenced.</p><p>Results: AAPA IgM was not detected in early life, but before RA onset, significantly more individuals were AAPA IgM positive (27.3%) compared to ACPA IgM positive (11.7%). Toward disease onset, ACPA IgM positivity increased to 51.2%, whereas AAPA IgM positivity remained stable. Furthermore, AMPAs developed in individuals who were AAPA IgM negative. Regarding B cell characteristics, germline-encoded BCRs were identified among both AAPA- and ACPA-expressing B cells in patients with RA.</p><p>Conclusion: AMPA responses in RA do not appear to arise solely from AAPA IgM, as suggested by the lack of association between predisease AMPA IgM positivity and later AMPA evolution. This is further supported by the presence of germline-configured ACPA BCRs, suggesting multiple possible starting points for AMPA responses. (Figure presented.).</p>